IBR-854

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameIBR-854
Drug Alias NameIBR854IBR-854
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > ACC-NKCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionAnti-Trophoblast glycoprotein
TargetsTrophoblast glycoprotein
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesImbioray (Hangzhou) Biomedicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImbioray (Hangzhou) Biomedicine Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A